Receive The Newest Study Notifications

Fight Colorectal Cancer (Fight CRC) has collaborated with Flatiron Health to develop a smartphone application for its Late-Stage, MSS-CRC Clinical Trial Finder. The first-of-its-kind app — now available for both iOS and Android — enables patients with...

Eli Lilly and Company announced results from its COAST-X Phase III clinical trial of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA) in patients who had no previous disease-modifying anti-rheumatic drug (bDMARD) treatment. The drug met the...

- Oral integrin antagonist inhibits multiple processes of pathologic fibrosis - Indalo to present at NASH Summit in Boston, MA, on April 24th Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from...

The University of Chicago will lead the NRG Oncology Statistics and Data Management Center (SDMC), which is receiving six more years of funding from the National Cancer Institute (NCI). “We are delighted that our institution is providing leadership on coordinating...

Nephure TM enzyme was evaluated vs. placebo in reduction of urinary oxalate associated with food oxalate, and will release results of the study May 4. We are delighted to be presenting our clinical results, which further confirm the efficacy and potency of our...

More drug-coated balloon (DCB) patients were event-free at six months compared to those treated with plain percutaneous transluminal angioplasty (PTA), according to global randomised trial demonstrating safety of a DCB in below-the-knee (BTK) use. London, UK, Thursday...

Oncology trials are becoming increasingly complex owing to the evolution of study designs (platform, basket and umbrella trials). eClinical technology has the capacity to accommodate the complexities of trial management. In this free webinar, learn how to efficiently...

In basket trials, cancers with differing histologies are pooled and the common element is a singular genetic mutation or protein alteration. The trial tests a drug that targets a common biologic process. This ability to assess numerous cancer types with one biomarker...

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine...

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB) approval to...

World’s First Phase 3 BET Bromodomain Epigenetics Trial Reaches Events Target Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that BETonMACE, the Company’s event-based, phase 3 registration trial has successfully reached 250 projected...

Senhwa Biosciences, Inc. (TPEx: 6492) announced today that the clinical trial of Silmitasertib (CX-4945) for the treatment of Basal Cell Carcinoma (BCC) has enrolled its first patient at Texas Oncology, Texas, USA. The trial will be carried out simultaneously across...

Researchers and scientists are constantly developing new, innovative medicines to effectively treat patients. However, the cost to conduct clinical trials and then receive approval to commercialize a drug is absurdly expensive. The Tufts Center for the Study of Drug...

The 16th annual observance of World Lupus Day on May 10 will highlight how emotional support helps people with lupus cope with its health effects and on the need for lupus clinical trial volunteers. World Lupus Day is sponsored by the World Lupus Federation, a global...

Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in July 2019 Interim efficacy data from ongoing open-label extension study expected in H2 2019...

Helps sponsors apply medical imaging in trials to advance development of NAFLD/NASH therapeutics. Bioclinica®, a leading provider of science and technology expertise to assist the life science industry in advancing the development of medical therapies, announced today...

-- United BioPharma's novel antibody suppresses HIV without eliciting resistance United BioPharma (UBP) today announced that its monoclonal antibody product, UB-421, is able to suppress HIV for at least four months in patients who previously paused their...

- Oral integrin antagonist inhibits multiple processes of pathologic fibrosis - Indalo to present at NASH Summit in Boston, MA, on April 24th Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from...

TrialAssure® – a leading, global software company focused on developing clinical trial transparency tools – announced today the launch of TrialAssure REGISTRY 2.5, the latest iteration of TrialAssure's premiere clinical trial registration and disclosure reporting...

The GAIN Trial will assess whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt progression of Alzheimer’s disease Researchers seek more than 500 participants in the United States and Europe; visit www.GAINtrial.com for information...